Half of all new drugs approved by the FDA are for patients with cancer, and approximately 10% of patients diagnosed with cancer have hematologic malignancies. Though hematologic malignancies are relatively rare, the number of publications, guidelines, and new drug approvals in this space is staggering.
I have focused solely on hematologic malignancies for more than 20 years, so I have a deep understanding of the therapeutic landscape and how patient management has evolved in this space. As a clinical pharmacist at heart, I think like a clinician and accurately synthesize and integrate new information into the treatment paradigm.
After two decades of working side by side with physicians, nurses, pharmacists, nurse practitioners, and physician assistants in a large academic medical center, I understand what is important to them, I know what questions to ask, and I have honed the soft skill of speaking to healthcare providers in their language.
I filter data presentation through a healthcare provider’s lens and present it in a way that is easy for them to understand. Having spent time in different healthcare organizations, I understand the decision-making structure and factors that influence treatment decisions from a systems perspective.
By providing direct patient care in the clinic, I made lasting friendships with patients with hematologic malignancies over multiple years of frequent visits. More than most people, I understand how cancer therapies affect the lives of patients and their families. The diversity in patient preferences and experience with treatment shines in the patient journeys I develop.
Having taught clinical trial interpretation for the past 20 years, I quickly see the strengths and limitations of data. Clients value my insights on the impact of a new therapeutic indication on the treatment landscape. They appreciate my assessment of the feasibility of implementing a new product in the community. I love to help my clients weave data, core messages, deadlines, and the details into a polished scientific story.